Mylan Inc (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

48.13USD
4:00pm EDT
Price Change (% chg)

$0.05 (+0.10%)
Prev Close
$48.08
Open
$48.01
Day's High
$48.15
Day's Low
$47.56
Volume
694,294
Avg. Vol
1,365,787
52-wk High
$57.52
52-wk Low
$34.59

MYL.OQ

Chart for MYL.OQ

About

Mylan Inc. (Mylan) is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan has two segments:Generics and Specialty. Its generic pharmaceutical business is conducted primarily in the United States and Canada... (more)

Overall

Beta: 1.19
Market Cap (Mil.): $17,984.20
Shares Outstanding (Mil.): 374.05
Dividend: --
Yield (%): --

Financials

  MYL.OQ Industry Sector
P/E (TTM): 32.73 32.39 33.40
EPS (TTM): 1.47 -- --
ROI: -- 17.97 17.27
ROE: -- 18.61 18.02
Search Stocks

DEALTALK-Amid tax inversion craze, some U.S. companies get cold feet

NEW YORK, Aug 25 - The headline noise may suggest otherwise but U.S. companies' interest in tax-driven deal-making may be starting to cool down.

25 Aug 2014

U.S. judge blocks FDA rule allowing generic versions of Hospira drug

- A federal judge has issued a temporary restraining order against the U.S. Food and Drug Administration's decision to allow the sale of generic versions of the Hospira Inc sedative Precedex.

20 Aug 2014

U.S. judge blocks FDA rule allowing generic versions of Hospira drug

- A federal judge has issued a temporary restraining order against the U.S. Food and Drug Administration's decision to allow the sale of generic versions of the Hospira Inc sedative Precedex.

20 Aug 2014

U.S. judge blocks FDA rule allowing generic versions of Hospira drug

Aug 20 - A federal judge has issued a temporary restraining order against the U.S. Food and Drug Administration's decision to allow the sale of generic versions of the Hospira Inc sedative Precedex.

20 Aug 2014

UPDATE 1-Meda lowers outlook after Q2 profit lags expectations

* Shares fall 6 percent (Adds detail, background, shares)

13 Aug 2014

Mylan presses on with tax-inversion Abbott deal

- Political opposition to tax-inversion deals will not stop Mylan Inc's purchase of some non-U.S. businesses from Abbott Laboratories , Chief Executive Heather Bresch said, even as some companies have backed away from such tax arrangements.

07 Aug 2014

UPDATE 2-Mylan presses on with tax-inversion Abbott deal

* CEO: Tax-inversion deals do not stop companies paying US taxes

07 Aug 2014

Mylan narrows full-year revenue, profit forecast

Aug 7 - Generic drug maker Mylan Inc narrowed its full-year revenue and earnings forecast, citing delays in U.S. Food and Drug Administration approval of key products.

07 Aug 2014

Deals of the day- Mergers and acquisitions

(Adds Allergan, Blackstone, 3M, Elliott, Intralot Czech, ONGC, Weltbild, Love Culture, GE, Telefonica, UniCredit, Ferrero; updates Time Warner)

16 Jul 2014

UPDATE 3-Abbott beats profit estimate, infant formulas rebound

(Adds CEO comments, details on formula sales, updates shares)

16 Jul 2014

Competitors

  Price Change
Dr. Reddy's Laboratories Limited (REDY.NS) Rs2,947.90 +25.15
Johnson & Johnson (JNJ.N) $102.95 -0.27
Pfizer Inc. (PFE.N) $29.38 -0.11
Novartis AG (NOVN.VX) CHF82.00 -0.30
Merck & Co., Inc. (MRK.N) $60.00 -0.28
Roche Holding Ltd. (ROG.VX) CHF267.10 -1.10
Abbott Laboratories (ABT.N) $42.35 -0.25
Bayer AG (BAYGn.DE) €101.15 -0.50
Bayer AG (BAYE.F) -- --
GlaxoSmithKline plc (GSK.L) 1,463.00p 0.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks